Semaglutide in India: A Complete Patient Guide
Semaglutide has become one of the most discussed GLP-1 receptor agonists in India—for both blood sugar control and weight management. Whether you have heard about it from your diabetologist or read about generic versions entering the market, understanding the drug class (not just brand names) helps you make informed decisions with your doctor. This guide covers forms, dosing, costs, safety, and what CDSCO, RSSDI, and ICMR guidance mean for Indian patients considering or already using this molecule within the broader GLP-1 family. Generic competition, oral versus injectable choices, and out-of-pocket budgeting make 2026 a pivotal year for patients navigating this medicine responsibly under Schedule H rules.
Jun 15, 2026 · 27 min read
Short answer
Semaglutide is a once-weekly or daily GLP-1 receptor agonist prescribed in India for type 2 diabetes and, in selected adults, obesity when BMI is ≥27.5 kg/m² or ≥25 with comorbidities per ICMR and RSSDI guidance. It requires prescription, gradual dose titration, and CDSCO-approved sourcing. Monthly costs range roughly ₹8,000–₹20,000 with generic options lowering expense. Oral and injectable forms differ in timing and storage. Kesho educates only—we do not prescribe or sell medications. Always verify CDSCO approval before purchase from licensed pharmacies only.
Key takeaways
- •Semaglutide is a GLP-1 receptor agonist—a drug class molecule—not a lifestyle product; CDSCO approval and Schedule H prescription are mandatory.
- •Weekly injection and daily oral forms are both available in India; each has distinct timing, storage, and titration requirements.
- •RSSDI recommends GLP-1 RAs including semaglutide when metformin and lifestyle are insufficient, especially with cardiovascular or obesity comorbidity.
- •CDSCO-approved generic semaglutide may lower costs 20–40%, but only licensed pharmacies with valid prescriptions are safe sources.
- •Nausea during titration is expected; slowing escalation and adjusting Indian meal patterns usually improves tolerance within weeks.
- •Long-term success pairs pharmacotherapy with medical nutrition therapy, quarterly follow-up, and CDSCO-approved sourcing from licensed pharmacies only.
At a glance (India)
| Drug class | GLP-1 receptor agonist |
|---|---|
| Injection frequency | Once weekly (subcutaneous pen) |
| Oral dosing | Daily, empty stomach, 30 min before food |
| Typical titration (injection) | 0.25 mg → 0.5 mg → 1 mg+ over weeks |
| Monthly cost range (2026) | ₹8,000–₹20,000 out of pocket |
| Regulatory status | Schedule H; CDSCO-approved products only |
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist—a medication that mimics the gut hormone GLP-1 to improve insulin release, reduce glucagon, slow stomach emptying, and decrease appetite. It belongs to a drug class, not a single brand. In India, semaglutide is approved by CDSCO for adults with type 2 diabetes and for chronic weight management in selected patients meeting BMI and comorbidity criteria aligned with ICMR and RSSDI guidance. Clinical trials including the SUSTAIN series (diabetes) and STEP programme (obesity) demonstrated meaningful HbA1c reductions and weight loss when combined with lifestyle changes. Semaglutide is a Schedule H prescription-only medicine. Kesho does not prescribe or sell semaglutide; this guide is for education so you can discuss options knowledgeably with your endocrinologist or diabetologist. When patients say they "started semaglutide," they are starting a molecule within the GLP-1 drug class—your prescription will name a specific CDSCO-approved product, but the clinical principles below apply to the class mechanism. India's growing generic market makes understanding the molecule itself more important than memorising packaging colours or marketing claims.
- Semaglutide
- A long-acting GLP-1 receptor agonist available as weekly injection or daily oral tablet, used for type 2 diabetes and obesity under medical supervision.
What forms of semaglutide are available in India?
Indian patients may encounter semaglutide in several formulations. Subcutaneous injection pens are typically dosed once weekly, starting at a low dose and increasing gradually over weeks—a process called dose titration that reduces nausea. Oral semaglutide tablets are taken daily on an empty stomach with a small amount of water, at least 30 minutes before food. Both forms require CDSCO approval and valid prescription. Following patent developments, CDSCO-approved generic semaglutide products have entered the Indian market, often at lower price points than innovator products. Always verify packaging for manufacturer name, batch number, expiry date, and storage instructions. Injectable pens require refrigeration (2°C–8°C) before first use; after opening, most can be stored below 30°C for several weeks per label instructions. Oral tablets may suit patients with needle phobia but demand strict morning routines—skipping the empty-stomach rule reduces absorption and effectiveness.
Who may benefit from semaglutide in India?
For type 2 diabetes, RSSDI guidelines position GLP-1 RAs including semaglutide when metformin and lifestyle measures are insufficient, particularly when cardiovascular risk, obesity, or hypoglycaemia concerns favour this class. For weight management, Indian thresholds often apply earlier than Western cut-offs: BMI ≥27.5 kg/m² without comorbidities, or ≥25 kg/m² with conditions such as prediabetes, hypertension, dyslipidaemia, fatty liver, or obstructive sleep apnoea per ICMR obesity guidance. The thin-fat phenotype common in South Asians means metabolic risk may be significant even at modest BMI—waist circumference and visceral fat matter alongside the scale. Eligibility requires physician assessment of thyroid history, pancreatitis risk, kidney function, pregnancy status, and drug interactions. Semaglutide is not appropriate for type 1 diabetes or diabetic ketoacidosis. Patients with established cardiovascular disease may receive particular benefit based on outcome trial data, but prescribing remains individualised.
How does semaglutide dosing and titration work?
Semaglutide dosing follows a gradual escalation schedule set by your doctor. For weekly injection, treatment typically begins at 0.25 mg weekly for four weeks, then increases stepwise to therapeutic doses of 0.5 mg, 1 mg, or higher depending on indication and tolerance. Oral semaglutide starts at 3 mg daily, then 7 mg, then 14 mg. Skipping titration steps or self-adjusting doses increases nausea, vomiting, and discontinuation risk. Most gastrointestinal side effects peak in the first four to eight weeks and improve as the body adapts. Take injections on the same day each week, rotating injection sites (abdomen, thigh, upper arm). If you miss a weekly dose by more than five days, skip and resume on your regular schedule—do not double dose without medical advice. During Indian festival seasons when routine is disrupted, set phone reminders for injection day and carry travel storage guidance if visiting relatives without refrigerator access.
Semaglutide formulations at a glance
| Feature | Weekly injection | Oral tablet |
|---|---|---|
| Frequency | Once weekly | Once daily |
| Administration | Subcutaneous pen | Empty stomach, 30 min before food |
| Typical titration | 0.25 → 0.5 → 1 mg+ | 3 → 7 → 14 mg |
| Storage | Refrigerate before use | Room temperature per label |
| Common trade-off | Needle use; strong trial data | Strict timing; no food/drink for 30 min |
What does semaglutide cost in India in 2026?
Out-of-pocket semaglutide costs in India vary widely by city, pharmacy, dose, and innovator versus generic product. Monthly expenses for injectable semaglutide commonly range from approximately ₹8,000 to ₹20,000; oral formulations may differ. Generic semaglutide approved by CDSCO can reduce costs but should be purchased only from licensed pharmacies with prescription. Beware of social-media sellers, unapproved imports, and compounded products—CDSCO has issued advisories against these. Health insurance rarely covers obesity indications; some corporate policies may partially cover diabetes indications. Discuss cost sustainability with your doctor early, as discontinuation without lifestyle support often leads to weight regain. Tier-2 city patients sometimes travel to metro pharmacies for competitive pricing; compare final invoice including GST. Titration months at lower doses may cost slightly less—buy one pen at a time during escalation if cash flow is tight.
Never purchase semaglutide without a valid prescription from a registered medical practitioner. Unapproved sources carry risks of counterfeit, degraded, or incorrectly dosed products.
What safety issues should Indian patients know?
Common side effects include nausea, bloating, constipation, and occasional diarrhoea—usually mild and transient during titration. Serious but rare risks include pancreatitis, gallbladder disease, and allergic reactions. Semaglutide carries a precaution for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). It is not recommended in pregnancy or breastfeeding. Kidney function should be monitored, especially if dehydration from vomiting occurs during Indian summers. Alcohol may worsen nausea. Always inform your doctor of all medications, including ayurvedic supplements, as interactions are possible. Report persistent abdominal pain, severe vomiting, or neck lumps promptly. CDSCO pharmacovigilance programmes track adverse events—your doctor may report serious reactions to strengthen Indian safety data.
How does semaglutide compare with other GLP-1 RAs in India?
| Feature | Semaglutide | Liraglutide | Dulaglutide |
|---|---|---|---|
| Dosing frequency | Weekly (injection) or daily (oral) | Daily injection | Weekly injection |
| Weight loss evidence | Strong (STEP trials) | Moderate | Moderate |
| Generic availability (2026) | Yes (CDSCO-approved) | Limited | Limited |
| Typical monthly cost | ₹8,000–₹20,000 | ₹6,000–₹12,000 | ₹8,000–₹18,000 |
| RSSDI positioning | Preferred when indicated | Established option | Established option |
What monitoring does your doctor recommend on semaglutide?
RSSDI suggests regular HbA1c every three months until stable, then every six months for many patients. Kidney function, lipids, and liver enzymes are checked periodically—especially if you have NAFLD or take other metabolic medicines. Blood pressure and weight should be tracked at each visit. If you have diabetic retinopathy, rapid glucose improvement may require ophthalmology review. Thyroid symptoms warrant examination regardless of GLP-1 use. Home glucose monitoring frequency depends on your regimen; semaglutide alone rarely causes hypoglycaemia, but combinations with sulfonylureas change that risk. Bring a log of nausea episodes, weight, and any missed doses to appointments. Monitoring is not optional—it confirms the medicine is helping enough to justify ongoing cost and detects complications early.
Ask your pharmacy to demonstrate pen technique on the first fill. Many hospital diabetes clinics in India offer free injection teaching—a five-minute session prevents bruising and improves confidence.
What practical tips help Indian patients succeed on semaglutide?
Nutrition: shift from large evening thalis to smaller plates with adequate protein (dal, paneer, eggs, fish). Timing: take oral doses before your morning chai if that is your earliest intake—water only for 30 minutes. Travel: carry a medical letter and store pens in a cooler bag on trains and flights. Cost: compare two licensed pharmacies and ask about generic CDSCO-approved alternatives. Community: tell family that smaller portions are intentional to reduce social pressure at meals. Expectations: STEP trial averages do not guarantee individual results—Indian patients with lower starting BMI may see smaller absolute weight change but meaningful metabolic improvement. Combine medicine with walking after dinner—a habit that aligns well with RSSDI lifestyle recommendations and tolerates slower gastric emptying.
How do you travel with semaglutide across India?
Domestic air travel allows prescription medicines in cabin baggage; carry the prescription, pharmacy invoice, and original packaging. Use an insulated pouch with ice packs for unopened pens—airport security may ask about injectables. Train journeys during summer require planning: never leave pens in hot compartments. If staying with relatives without reliable refrigeration, ask your pharmacist about in-use storage limits below 30°C. Set weekly injection reminders before weddings, pilgrimages, or work conferences when routine shifts. If you cross time zones on international travel, ask your endocrinologist how to adjust injection day. Oral semaglutide is easier to transport but still needs empty-stomach discipline in hotel rooms. CDSCO-approved products should remain in original packaging with batch labels visible for any inspection.
What lifestyle changes maximise semaglutide results?
RSSDI and ICMR both position pharmacotherapy as an adjunct to medical nutrition therapy and physical activity—not a replacement. Protein adequacy prevents muscle loss during rapid weight change: target dal, sambar, paneer, eggs, or fish distributed across meals. Resistance exercise twice weekly preserves lean mass. Sleep and stress management affect glucose and eating behaviour independently of medication. Alcohol reduction supports fatty liver improvement and reduces nausea. Track portions with smaller steel katoris when appetite signals are blunted—you still need micronutrients even when not hungry. Festival planning prevents binge cycles that destabilise both glucose and GI tolerance. Patients who invest in lifestyle alongside semaglutide consistently report better satisfaction, lower total medicine doses over time, and more durable results if therapy is ever tapered.
When might your doctor choose a different GLP-1 RA?
Semaglutide is one molecule within the GLP-1 drug class—not the only option. Your doctor may prefer liraglutide if daily dosing suits your routine better, or dulaglutide if weekly injection with a different device profile fits your hand dexterity. Tirzepatide—a dual GIP/GLP-1 agonist—may be discussed when greater weight loss is needed and cost is acceptable, though it is typically more expensive in India. If nausea persists despite slow semaglutide titration, switching within the class sometimes improves tolerance. Cardiovascular and kidney comorbidities influence selection per RSSDI algorithms. Cost and generic availability increasingly steer Indian prescribing toward CDSCO-approved semaglutide, but clinical factors always come first. Never switch medicines without professional supervision—dose equivalents do not translate directly between molecules. Document prior attempts before requesting escalation to another drug-class member.
Bring your prescription, insurance card, and last three HbA1c reports to every follow-up. Indian specialists often have limited appointment time—organised records speed shared decision-making on dose, cost, and side effects.
What questions should you ask before starting semaglutide?
Ask your endocrinologist: Which formulation fits my adherence profile and budget? What titration schedule will we follow and what nausea strategies are planned? Which labs will you monitor and how often? How does semaglutide interact with my current diabetes tablets or supplements? What monthly cost should I budget for twelve months including generics? When will we reassess whether benefits justify continuation? What is the plan if I cannot afford maintenance doses? RSSDI-aligned doctors welcome these questions—cost and adherence are part of ethical prescribing in India. Write answers in your phone notes and share with family members who help manage your healthcare. If oral semaglutide is discussed, confirm the empty-stomach routine against your morning schedule including prayer, commute, and tea habits. Clarify CDSCO-approved product names before visiting the pharmacy to avoid substitution surprises.
How does semaglutide affect kidney function in Indian patients?
Chronic kidney disease is common in Indian type 2 diabetes, often developing at younger ages than in Western populations. GLP-1 receptor agonists including semaglutide are frequently favoured when kidney disease coexists with diabetes because they support glycaemic control without promoting weight gain or hypoglycaemia like some older agents. Severe renal impairment may require dose adjustment or specialist supervision. Dehydration from vomiting during titration can temporarily worsen kidney markers—fluid intake matters especially during Indian summers. RSSDI pathways increasingly position GLP-1 RAs in diabetic kidney disease management alongside SGLT2 inhibitors when appropriate. Bring recent creatinine and eGFR results to your consultation. Semaglutide does not replace nephrology follow-up, blood pressure control, or dietary sodium management in CKD.
Semaglutide combinations commonly used in India
| Companion medicine | Typical RSSDI approach | Key caution |
|---|---|---|
| Metformin | Usually continued | Monitor GI tolerance with combined nausea |
| SGLT2 inhibitor | Often added if targets unmet | Hydration; genital infection awareness |
| Sulfonylurea | Dose often reduced | Hypoglycaemia risk rises |
| Basal insulin | Specialist-guided combination | Glucose monitoring intensified |
| Ayurvedic glucose remedies | Disclose to doctor | Undisclosed stacking risks hypoglycaemia |
How do CDSCO-approved generics compare with innovator semaglutide?
Following patent developments, multiple Indian manufacturers offer CDSCO-approved generic semaglutide injectables and oral formulations. Bioequivalence studies demonstrate comparable active ingredient exposure to reference products when manufactured and stored correctly. Price differences of twenty to forty percent are common at licensed pharmacies. Innovator products may offer familiar pen devices or established supply chains in some cities. Your doctor can prescribe by molecule name, allowing pharmacist substitution per local regulations with your consent. Extreme discounts from unverified sellers remain a counterfeit risk regardless of generic versus innovator labelling. Verify batch numbers, expiry dates, and cold-chain handling at purchase. RSSDI does not prefer innovator over generic when both hold CDSCO approval—the clinical molecule is identical within the GLP-1 drug class. Ask your pharmacist to confirm the generic manufacturer on first fill and report any device or tolerance differences at follow-up.
STEP trial participants lost roughly ten to fifteen percent of body weight over sixty-eight weeks—but trial averages are not personal guarantees. Indian patients with lower starting BMI may see smaller scale changes while still gaining meaningful HbA1c and waist improvements.
How should you manage expectations on semaglutide?
Social media showcases dramatic before-and-after photos that rarely reflect typical Indian clinic experience. Semaglutide works gradually through dose titration—meaningful weight change often appears after eight to twelve weeks, not days. Patients with BMI near ICMR thresholds may improve metabolic labs before the scale moves dramatically. Muscle preservation requires adequate protein and resistance exercise; rapid loss without nutrition planning causes fatigue and regain risk. Cost sustainability over twelve to twenty-four months determines whether short-term success becomes long-term health. Discuss stopping rules and maintenance plans before starting, not only when refills become unaffordable. RSSDI and ICMR frame semaglutide as one tool in chronic disease management—not a cosmetic shortcut or guaranteed outcome. Realistic expectations improve adherence and reduce disappointment during the nausea-heavy first month.
When might semaglutide not be the right choice?
Semaglutide is inappropriate for type 1 diabetes, pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and recent severe pancreatitis. Caution applies in severe gastroparesis, active inflammatory bowel disease flare, and frail elderly with low BMI. Patients who cannot afford maintenance dosing may be better served delaying initiation until budget is secure—intermittent sub-therapeutic use wastes money and causes side effects without benefit. Needle phobia unresponsive to training may favour oral semaglutide or another GLP-1 RA with different device. If tirzepatide is clinically indicated but semaglutide is prescribed solely for cost, understand the trade-off explicitly with your doctor. Declined prescribing is not personal rejection—it reflects CDSCO contraindications and ethical ICMR frameworks.
How do you prepare for your first semaglutide consultation?
Arrive with HbA1c within three months, kidney and liver tests, medication list including supplements, and weight history. Ask which CDSCO-approved product names your pharmacy stocks locally. Discuss oral versus injectable routes against your morning routine, needle preference, and budget. Request written titration schedule and nausea management plan compatible with your diet—vegetarian, Jain, or non-vegetarian. Schedule four-week follow-up before leaving. Clarify missed-dose rules and summer storage. Preparation converts a fifteen-minute slot into durable shared decision-making.
What long-term success looks like on semaglutide in India?
Successful semaglutide patients in Indian clinics typically show sustained HbA1c improvement or weight reduction aligned with doctor-set targets, tolerate maintenance doses without debilitating nausea, and afford refills without treatment gaps. They pair injection or oral dosing with medical nutrition therapy, regular activity, and quarterly follow-up. They source CDSCO-approved products from licensed pharmacies, store pens correctly during summer, and report side effects early rather than stopping silently. Long-term success is not a specific kilogram number—it is metabolic stability, manageable cost, and habits that persist if medication is ever tapered. RSSDI and ICMR frame semaglutide as one component of chronic care; patients who treat it as a complete solution often disappoint themselves when appetite returns after stopping. Celebrate lab improvements and waist changes even when scale movement is modest—especially for thin-fat phenotype patients near ICMR BMI thresholds.
What should you remember about semaglutide as a drug-class molecule?
Semaglutide is one GLP-1 receptor agonist within a regulated drug class—not a lifestyle brand. CDSCO approval, Schedule H prescription, licensed dispensing, and physician monitoring apply to innovator and generic products alike. Understanding mechanism, titration, cost, and safety as class principles helps you partner with your endocrinologist while filtering social-media noise about compounded peptides and unapproved imports. Prepared patients ask better questions at follow-up.
Frequently asked questions
Is semaglutide available as a generic in India?
How much weight can I expect to lose on semaglutide?
Can I stop semaglutide once I reach my goal weight?
Does semaglutide cause low blood sugar?
How is semaglutide different from tirzepatide?
Can vegetarians use semaglutide safely?
What is the difference between semaglutide 0.5 mg and 1 mg pens?
Can semaglutide be used after bariatric surgery?
How do I store semaglutide during Indian monsoon humidity?
Find a legitimate specialist
Kesho educates only. we do not prescribe, sell medicines, or book appointments. GLP-1 medicines are Schedule H in India and must be prescribed by an endocrinologist, internal medicine specialist, or cardiologist after proper evaluation. Avoid chemists or wellness clinics offering pens without prescription.
RSSDI-accredited centres in Your city
Jethwani Diabetes Care Centre, Jethwani Hospital
Dr. Pratap Jethwani
5-Junction plot, Near post office, Rajkot 360001
9824285957
Full national list: RSSDI accredited centres
People also ask
Is semaglutide the same as tirzepatide?
No. Semaglutide activates GLP-1 receptors only. Tirzepatide is a dual GIP/GLP-1 receptor agonist—a related but distinct drug class molecule. Dosing, cost, and individual tolerance differ. Your endocrinologist selects based on clinical need, not social media trends.
How do I know if my semaglutide is CDSCO-approved?
Check the package insert for manufacturer details, batch number, and expiry. Your pharmacist can confirm approval status. Avoid products sold without prescription on messaging apps—CDSCO has warned against unapproved imports and compounded alternatives.
Can I switch from injection to oral semaglutide?
Sometimes, under medical supervision. Doses are not interchangeable milligram for milligram. Switching requires a new titration schedule and cost comparison. Discuss adherence, nausea history, and needle preference with your diabetologist.
What should I do if I miss a weekly injection?
If fewer than five days have passed since the missed dose, take it as soon as you remember. If more than five days have passed, skip the missed dose and resume on your regular day. Never double a dose without medical advice.
Does semaglutide interact with metformin?
Metformin is commonly continued alongside semaglutide and is often first-line per RSSDI. Combined use is standard for type 2 diabetes. Your doctor may adjust other medicines—especially sulfonylureas or insulin—to reduce hypoglycaemia risk.
Can semaglutide help with fatty liver in Indians?
Weight loss of 5–10% can reduce hepatic steatosis in many patients with NAFLD. GLP-1 RAs including semaglutide are increasingly discussed in metabolic liver disease management, but individual assessment is required. Alcohol reduction remains essential.
Is semaglutide safe during pregnancy?
No. Semaglutide is not recommended during pregnancy or breastfeeding. If you are planning pregnancy, discuss stopping timelines and alternative glucose management with your doctor well in advance.
How long should I stay on semaglutide?
For type 2 diabetes, many patients use GLP-1 RAs long term for glycaemic and cardiovascular benefit. For obesity, duration depends on goals, tolerance, cost, and lifestyle maintenance. Stopping without a plan often leads to weight regain.
Will generic semaglutide work as well as innovator products?
CDSCO-approved generics must demonstrate bioequivalence to reference products. When sourced from licensed pharmacies with proper storage, they should deliver equivalent active ingredient exposure. Extreme discount offers remain a counterfeit risk.
Can I exercise normally while on semaglutide?
Yes—and RSSDI and ICMR encourage physical activity alongside pharmacotherapy. Start gradually if you are new to exercise. Stay hydrated, especially during titration when nausea may limit intake. Resistance training helps preserve muscle during weight loss.
Does semaglutide affect thyroid function tests?
Semaglutide does not routinely alter thyroid hormone levels in patients without thyroid disease. Contraindications apply to personal or family history of medullary thyroid carcinoma and MEN2—not general thyroid nodules. Report neck lumps, hoarseness, or swallowing difficulty promptly regardless of GLP-1 use.
How do I dispose of used semaglutide pens in India?
Place used needles in a puncture-proof sharps container and follow local biomedical waste guidelines. Many hospital pharmacies accept sharps disposal. Never recap needles or discard loose pens in household rubbish—this risks needle-stick injury to waste handlers.
References
Tier 1: ICMR, CDSCO, RSSDI, WHO. Tier 2: PubMed / peer-reviewed journals. Tier 3: supplementary.
- T1RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus (2023). Research Society for Study of Diabetes in India. rssdi.in/
- T1Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 384(11), 989-1002. pubmed.ncbi.nlm.nih.gov/33567185/
- T1CDSCO. Drug Alerts and Advisories on GLP-1 Receptor Agonists. Central Drugs Standard Control Organisation, Govt. of India. cdsco.gov.in/
- T1ICMR Expert Group. (2024). National Guidelines for Obesity Management in India. Indian Council of Medical Research. icmr.gov.in/
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026
View markdown version · semaglutide-india-complete-guide.md (for AI agents)
Prepare for your doctor visit
Take our educational assessment to identify discussion topics, not eligibility.
Related guides
BasicsOral vs Injectable Semaglutide in India: Which Form Fits You?
Semaglutide arrives in Indian clinics as a weekly pen and as a daily tablet—same GLP-1 receptor agonist, very different routines. Patients often ask which form is "better," but the honest answer depends on adherence, lifestyle, clinical goals, and cost in your city—not a universal winner.
Read guide →BasicsOral Semaglutide in India: What Patients Should Know
Not everyone wants weekly injections. Oral semaglutide brings GLP-1 receptor agonist therapy to a daily tablet—with strict morning rules that conflict with Indian bed tea, haldi doodh, and early breakfast habits. Understanding absorption requirements, cost reality versus injectable generics, and who truly benefits from tablets versus pens helps you discuss format choice with your endocrinologist rather than assuming pills are easier or cheaper by default.
Read guide →
BasicsGLP-1 Explained: A Complete Guide for Indian Patients
If you have heard about semaglutide or tirzepatide and wondered whether they are right for you, you are not alone. GLP-1 receptor agonists have changed how doctors approach type 2 diabetes and obesity worldwide—and India is no exception. This guide explains what GLP-1 medications are, how they work in the body, and what matters specifically for Indian patients navigating access, cost, and safety under RSSDI, ICMR, and CDSCO frameworks. Whether you are newly diagnosed with type 2 diabetes, managing central obesity with normal-range BMI, or supporting a family member exploring options, understanding the drug class—not brand marketing—is the foundation for productive medical conversations. South Asian patients face unique metabolic patterns, lower insurance coverage, and growing generic access that make drug-class literacy more valuable than ever in 2026.
Read guide →
India AccessCheapest GLP-1 Options in India: A Drug-Class Cost Guide
"Cheapest GLP-1" searches spike every month in India—but the answer is not a single product name. Costs differ across the GLP-1 receptor agonist drug class by molecule, formulation, dose, city, and whether you choose CDSCO-approved generics. This guide compares class-level economics so you can discuss value with your doctor, not chase unsafe discounts.
Read guide →